Neoadjuvant intratumoral immuno-gene therapy for non-small cell lung cancer

Discovery Medicine 2016 April 21 [Link] Non-small Cell Lung Cancer (NSCLC) remains a deadly disease despite aggressive treatment protocols which incorporate chemotherapy, radiation and surgery. These traditional approaches have reached a plateau in therapeutic benefit. There is emerging evidence suggesting that immunotherapy can serve as an alternative treatment modality for NSCLC. Our group has nearly…

Read More

Massive chest wall resection and reconstruction for malignant disease.

Onco Targets and Therapy 2016 April 19 [Epub ahead of print] [Link] Foroulis CN, Kleontas AD, Tagarakis G, Nana C, Alexiou I, Grosomanidis V, Tossios P, Papadaki E, Kioumis I, Baka S, Zarogoulidis P, Anastasiadis K. Abstract OBJECTIVE: Malignant chest wall tumors are rare neoplasms. Resection with wide-free margins is an important prognostic factor, and…

Read More

A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma.

European Journal of Cancer (Oxford, England: 1990) 2016 May 5 [Epub ahead of print] [Link] Minchom A, Punwani R, Filshie J, Bhosle J, Nimako K, Myerson J, Gunapala R, Popat S, O’Brien ME. Abstract BACKGROUND: Dyspnoea is one of the commonest symptoms of lung cancer. Opioids can reduce dyspnoea. This study investigates acupuncture for relief…

Read More

BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions

Diagnostic cytopathology 2016 April 28 [Epub ahead of print] [Link] Walts AE, Hiroshima K, McGregor SM, Wu D, Husain AN, Marchevsky AM. Abstract BACKGROUND: Loss of BAP1 by immunohistochemistry (IHC) and CDKN2A(p16) deletion by fluorescence in situ hybridization (FISH) have been proposed to distinguish malignant mesothelioma (MM) from atypical reactive mesothelial proliferations (ARMP) in effusions but…

Read More

A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma

Journal of applied clinical medical physics / American College of Medical Physics. 2016 Mar 8;17(2):5980. doi: .[Link] Runxiao L1, Yankun C, Lan W. Abstract Malignant pleural mesothelioma (MPM) is an extremely difficult disease to treat. This pilot study investigates the feasibility of using volumetric-modulated arc therapy (VMAT) for malignant pleural mesothelioma (MPM), and compares VMAT…

Read More

Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model

International Journal of Oncology 2016 February 1 [Epub ahead of print] [Link] Abu Lila AS, Kato C, Fukushima M, Huang CL, Wada H, Ishida T. Abstract Malignant pleural mesothelioma (MPM) is an incurable cancer with an increasing incidence. Currently, pemetrexed (PMX)-based chemotherapy is the mainstay of chemotherapy for MPM, however, the outcome of PMX-based chemotherapy…

Read More